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Abstract
Background: The prevalence of amphetamine-type stimulant use is greater than that of opioids and cocaine
combined. Currently, there are no approved pharmacotherapy treatments for amphetamine-type stimulant
problems, but some face-to-face psychotherapies are of demonstrated effectiveness. However, most treatment
services focus on alcohol or opioid disorders, have limited reach and may not appeal to users of amphetamine-type
stimulants. Internet interventions have proven to be effective for some substance use problems but none has
specifically targeted users of amphetamine-type stimulants.
Design/method: The study will use a randomized controlled trial design to evaluate the effect of an internet
intervention for amphetamine-type stimulant problems compared with a waitlist control group. The primary
outcome will be assessed as amphetamine-type stimulant use (baseline, 3 and 6 months). Other outcomes
measures will include ‘readiness to change’, quality of life, psychological distress (K-10 score), days out of role, poly-
drug use, help-seeking intention and help-seeking behavior. The intervention consists of three modules requiring
an estimated total completion time of 90 minutes. The content of the modules was adapted from face-to-face
clinical techniques based on cognitive behavior therapy and motivation enhancement. The target sample is 160
men and women aged 18 and over who have used amphetamine-type stimulants in the last 3 months.
Discussion: To our knowledge this will be the first randomized controlled trial of an internet intervention
specifically developed for users of amphetamine-type stimulants. If successful, the intervention will offer greater
reach than conventional therapies and may engage clients who do not generally seek treatment from existing
service providers.
Trial registration: Australian and New Zealand Clinical Trials Registry (www.anzctr.org.au/) ACTRN12611000947909
Keywords: Amphetamine related disorders, Internet, World wide web, Randomized control trial, Cognitive therapy
Background
Amphetamine-type stimulants (ATS) include an array of
psychoactive substances, the most commonly used illicit
ATS being methamphetamine, amphetamine and ecstasy
(3,4-Methylenedioxymethamphetamine) [1,2]. There are
now an estimated 35 million ATS users worldwide
compared with combined total of 29 million opioid and
cocaine consumers [3,4]. The age of initiation of ATS is
typically in the mid-late teens, with levels of use often
peaking in early adulthood. In Australia, the lifetime
prevalence of use is highest among those aged 20-
29 years (ecstasy 25%, meth/amphetamine 15%), with
the respective 12-month figures being 10% and 6%
among the same age group [5].
While the bulk of ATS use is recreational in nature,
this population includes a sizable proportion of people
who become dependent and experience chronic debili-
tating health problems as a result of their use of ATS
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[6]. Major health concerns include paranoia, aggression,
increased risk of stroke and cardiovascular pathology [7].
Dependence on ATS, like dependence on any drug, is
typically associated with a reduction in quality of life,
premature mortality and elevated levels of crime [8].
This is particularly the case with the use of more potent
ATS, such as crystalline methamphetamine, and with
more efficient routes of administration (e.g., smoking or
injecting) [9]. Reducing the impact of ATS use requires
the simultaneous development of effective management
strategies and methods to improve the uptake and acces-
sibility of treatments for this population. The spectrum
of ATS use will also need to be considered, from irregu-
lar use through to stimulant use disorders (abuse,
dependence) [10].
Despite the widespread use of ATS, a systematic re-
view concluded that, to date, there are insufficient data
to support the use of pharmacotherapies such as fluoxet-
ine, amlodipine, imipramine and desipramine in the
treatment of amphetamine abuse and dependence [11].
However, research continues to assess other potential
agents in the treatment of stimulant abuse [12,13]. A re-
view of psychosocial treatments for methamphetamine
dependence reported that the intensive application of
psychological interventions (e.g., contingency manage-
ment, cognitive behavior therapy (CBT), motivational
interviewing) can result in a moderate reduction in
stimulant use [14]. Brief cognitive behavioral interven-
tions, of up to four sessions duration, have also been
shown in previous research to be associated with signifi-
cant reductions in amphetamine use and significantly
greater likelihood of abstinence than controls [15]. How-
ever, these types of structured psychological interven-
tions are not widely implemented in community-based
treatments for drug use, and ATS users seeking help
from traditional drug and alcohol services frequently re-
port their needs are not being met [10]. For example,
among a sample of methamphetamine users in Queens-
land, Australia, the majority felt that more information
about methamphetamine use should be available and
more accessible outside treatment services and business
hours [16]. In particular, respondents reported that
needle and syringe programs, methadone maintenance
programs and outpatient counseling should not be co-
located, as doing so is viewed as a key barrier to treat-
ment access. The need to develop appropriate, novel
treatments that are well accepted by ATS communities
is clear, including options for accessing treatments out-
side mainstream specialist treatment services [17].
Given that psychological treatments can reduce
stimulant use [15,18], there is the potential to develop
internet-based treatments for ATS users, with many
internet-based CBT treatment packages currently ac-
cessible via the world wide web [19]. The critical
advantage offered by web-based interventions for mental
health and substance use problems is that they have the
potential to greatly reduce key barriers to obtaining
treatment, in particular, stigma (given the anonymous
access), cost (with free treatment), reach (potentially
worldwide coverage and 24 hour access), especially for
those living outside of metropolitan areas [20,21]. This is
important in the context of ATS use, not only because
of the number of people potentially requiring treatment
but because surveys show that stimulant users are reluc-
tant to seek treatment from existing drug treatment ser-
vices as most are tailored toward clients with opiate or
alcohol problems [1,22]. Furthermore, for those with ad-
dictive disorders, access to treatment ‘24/7’ may be a
particularly important benefit of internet services, allow-
ing the potential to capitalize on times of high motiv-
ation to change behavior and access to resources when
the risk of relapse is high.
Internet-based interventions have already been demon-
strated as effective for the treatment of depression and a
range of anxiety disorders [23]. With respect to substance
use, web-interventions have been effective in reducing
problematic use of alcohol in young adults [24] and in re-
ducing cannabis use via school-based interventions that
involve on-line materials [25]. Brief internet interventions
have been shown to reduce drug use and ‘high-risk’ behav-
ior in human immunodeficiency virus (HIV) positive drug
users [26] and a computerized intervention using com-
bined CBT and motivational interviewing (MI) has been
reported to reduce cannabis and alcohol use among those
with co-morbid major depression [27]. However, the
current authors are not aware of any evaluated internet
based interventions for the use of ATS.
The objective of the study was to adapt existing face-
to-face psychological approaches (i.e., CBT and MI) for
delivery via the internet to reduce the use of ATS and
associated problems plus improve motivation to reduce
ATS use, with assessment of effectiveness at 3 and
6 months post-intervention.
Method
Design
A two-group randomized controlled trial will be used.
The intervention group will receive an internet interven-
tion consisting of three modules (detailed below). The
wait-list control group will undertake the same assess-
ments as the intervention group, with access to the
intervention site at 6 months post enrolment. In
addition, all participants will be provided with contact
details for emergency services.
Sample
Participants will be recruited via a variety of sources:
youth magazines, web-sites, social networking sites,
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universities and clinics. The inclusion criteria are: resi-
dent in Australia, aged 18 years or older and use of am-
phetamine type stimulants (e.g. meth/amphetamine,
ecstasy, non-medical use of prescription stimulants) in
the last 3 months. Furthermore, participants need to
have access to the internet, a valid e-mail address, tele-
phone access and to provide informed consent. The
exclusion criteria are: currently receiving any treatment
for stimulant abuse/dependence, currently receiving
pharmacotherapy for any substance use disorder (e.g.
methadone, naltrexone, buprenorphine) except nicotine
replacement therapy; self-reported lifetime diagnosis
with schizophrenia, schizoaffective, or bipolar disorder.
Procedure
Enrolment and screening will be undertaken via the
internet. Advertisements will direct participants to the
study web address. First, participants who visit the study
website will be given information on the project and
their eligibility assessed by means of a series of online
questions. Based on their answers, participants who are
not eligible for the study will be given information about
other potentially useful websites and resources (e.g.
mental health, alcohol or other drugs websites and help-
lines). Participants who are eligible for inclusion will be
asked to provide active consent by ‘clicking’ on a box for
each element of the consent form in order to enroll in
the study. Figure 1 illustrates the flow of participants
through the study. Participants will be asked to provide
an e-mail address that will be verified via a personalized
link in an automated email. This link will take partici-
pants to the study site where they will set their own
username and password. Participants will then be direc-
ted to an online baseline survey before being rando-
mized to study groups. The randomization process will
be fully automated with permuted blocks of four and
will be implemented within the program.
Participants who are assigned to the intervention group
will then be provided with immediate access to the first
module of the intervention. These participants will be
advised to allow 1 week between modules, but are
allowed to proceed at their own pace. Participants must
visit each page of a module in sequence to complete the
module and thus obtain access to the next one. The
intervention group will receive emails at seven day inter-
vals after the commencement of the trial period, either
asking them to start the next module, if they have not
already commenced that module, or inviting them to re-
visit the site. A further e-mail will be sent to those who
do not start the current module at 3 days after the mod-
ule was scheduled for commencement. Participants will
be invited via e-mail to complete follow-up assessment at
3 and 6 months (91 and 183 days) post-randomization
with a further two reminder emails at 7 day intervals if
required, followed by a telephone call(s) for participants
who do not respond to the emails. Participants will receive
AU$20 for baseline assessment and for each follow-up
questionnaire that they complete, paid as either on-line
vouchers or posted cheques.
The Australian National University Human Research
Ethics committee approved the study, which is also regis-
tered with the Australian and New Zealand Clinical Trials
Registry (www.anzctr.org.au/) ACTRN12611000947909.
Measures
Both the primary and secondary outcome measures will
be assessed at baseline, 3 and 6 month. The primary out-
come measure will be ATS use, assessed using the
World Health Organization Alcohol, Smoking, Sub-
stance Involvement Screening Test (ASSIST) [28,29].
The ASSIST first assesses lifetime use of nine categories
of drugs (i.e. tobacco, alcohol, cannabis, cocaine, ATS,
inhalants, sedatives, hallucinogens, opioids and other).
Then, for any drug identified by the lifetime question,
data relating to the last 3 months is collected on: fre-
quency of use, cravings, problems (health, social legal or
financial), and failure to fulfill roles. Next, the ASSIST
ascertains if a friend or relative has ever expressed con-
cern about their drug use and if the person has ever
tried and failed to control their drug use. Finally, injec-
tion of drugs is assessed. The standard ASSIST scoring
algorithm will be used to generate a score related to use
of ATS [28].
The secondary outcomes will be: (a) health-seeking
intention and help-seeking behavior measured with the
general help-seeking questionnaire (GHSQ) [30] and the
actual help-seeking questionnaire (AHSQ) [31,32]; (b)
readiness to change assessed using a modified version of
the Readiness to Change Questionnaire (RTCQ) [33]
referencing ATS rather than alcohol; (c) psychological
distress assessed using the Kessler 10 [34]; (d) poly-drug
use measured by the ASSIST [28]; (e) days out of role
[35]; and (f ) quality of life assessed by the European
Health Interview Survey (EUROHIS) Quality of Life
scale [36]. The baseline measures include demographic
information (e.g., age, sex, marital status), drug use his-
tory (age of first use of ATS), and severity of dependence
assessed using the Severity of Dependence Scale [37].
Both the GHSQ and AHSQ are designed to be modi-
fied to reflect the condition under investigation and rele-
vant potential sources of help [32]. The condition
investigated will be help-seeking for ‘a problem with
stimulant drug use’, with additions to the existing list of
potential sources of help including “drug information
services (e.g. internet, telephone)” and “specialist drug
services (e.g. in-person services)”. We will also modify
examples such as “school counselor” or “teacher” to re-
flect the target age group (“counselor” or “lecturer”).
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Recruitment (advert /website link)
Trial information
Module 1
Collect user input
Intervention (n=80)
7 days later
e-mail “logon for next module” or 
“revisit module”
Baseline data collection and payment
Wait list control
(n=80)
Create username/password
Confirm trial e-mail address
Randomised
Ineligible – exclude: 
‘thank for interest’ 
web link to other 
MH / AOD 
resources
Screening (see table 1)
Active online consent
Module 2
Collect user input
7 days later
e-mail “logon for next module” or 
“revisit module”
Module 3
Collect user input
Site evaluation survey
E-mail congratulations
Not accessed – reminder 
email (+3 days)
Not accessed – reminder 
email (+3 days)
Not accessed – reminder 
email (+3 days)
e-mail day 91 “logon follow-up data”
1st follow-up data collection, day 91 and
payment
E-mail thanks / end of study
2nd follow-up data collection, day 183 
and payment
1st follow-up data 
collection day 91 
and payment
e-mail day 183 “logon follow-up data 
collection”
Not accessed - 2 reminder 
emails (day 98, 105) then 
phone (day 112)
Not accessed - 2 reminder 
emails (day 190, 197) then 
phone (day 205)
Reminder e-mail 
E-mail thanks / 
payment – access to 
web-site
2nd follow-up data 
collection, day 183
and payment
(Reminders as per 
intervention group)
Figure 1 Participant flow through the study.
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Item scores will be summed on the two measures. The
RTCQ has 12 items, with four questions relating to each
of the stages: ‘pre-contemplation’; ‘contemplation’; and
‘action’. The five point Likert scales will be summed to
obtain scores on each stage, with participants designated
to their highest scoring stage, or in the event to tied
scores, the higher stage [33]. The K10 total score (max-
imum 50) will be used to quantify psychological distress
at each time point [34]. Poly-drug use will be defined as
the sum of ASSIST classes of drugs endorsed for the
past 3 months [29]. ‘Days out of role’ will be derived
from Kessler’s questions but referencing “ATS drug use
(e.g. methamphetamine, ecstasy, ice) “rather than “de-
pression” [35] and quality of life will be indexed as total
EUROHIS Quality of Life scores [36].
In addition, immediately after finishing the third mod-
ule, the intervention group will evaluate the intervention
content and study website. Satisfaction with the inter-
vention plus perceived benefits and negative aspects will
be assessed with a measure developed for the Wellbeing
study [38] but modified to reference “drug use” rather
than “depression”. Descriptive measures of completion
(e.g. number of modules and subsequently, follow-up
surveys) will be collected together with scores on the
Internet Intervention Adherence Questionnaire – 16
items evaluating barriers to internet treatment [39].
Table 1 provides a summary of the measures assessed at
each time point.
Estimation of the expected effect sizes and sample size
With three time points (baseline, 3 and 6 months) the
study is designed to detect an effect of f= .27. This
requires 60 people per group: to allow for attrition of
20% by 6 months we will recruit 80 people per group.
The development study for the ASSIST reported that in
an Australian sample of stimulant users, there was a sig-
nificant group by time interaction for those who
received a brief intervention compared to controls (with
64 and 65 people respectively per group), which had a
power of 84% to detect this effect [28]. Other brief in-
person motivational interventions have achieved moder-
ate sized effects on drug use measures (d= .63-.45) [40],
so the effect size postulated for this study is plausible.
Analysis
The primary analysis will be on an intention-to-treat
basis, using a mixed model repeated measures (MMRM)
approach. This overcomes many of the limitations of
traditional repeated measures analysis of variance, in
that it uses all available data without requiring substitu-
tion or estimation of missing values to avoid the exclu-
sion of cases with non-complete data and does not
assume homogeneity of correlations over waves of meas-
urement [41]. The effect of the intervention will be
assessed by an analysis of a time by group interaction. A
sensitivity analysis will be conducted using multiple im-
putation of missing data. Categorical outcome measures
will be evaluated using non-linear mixed models.
Content of modules
The theoretical approach reflected in the intervention
modules is motivational enhancement with use of CBT
based methods. The intervention draws on guidelines
for face-to-face treatment of amphetamine use [42]. The
underpinning philosophy is that of harm minimization,
with participants free to decide on the most appropriate
goals for themselves, including quitting completely, re-
ducing their drug use, taking a break from use, or using
in a less hazardous manner.
The first module examines the key problem areas on
which the use of ATS typically impacts. Participants ei-
ther select from a menu of items for each problem area
or record relevant problems that they have incurred.
The areas are: relationships with family and friends,
health, finances, work/study, legal issues, mental health,
and specific drug use problems (see Figure 2). Each page
of the intervention features four characters, with a devel-
oping storyline for each character that involves a prob-
lem relevant to that page; for example, problems that
have arisen in a work setting. The final page provides a
summary of the problems that the participant has
endorsed and guides the participant to generate a ‘map’
of the interconnections between problems.
Module two asks participants to think about the pros
and cons of their use of stimulants and the good and
bad things related to changing their behavior, an ap-
proach based on the model of Miller and Rollnick [43].
To aid in their ‘decision balance’ for each good or bad
element that they select, participants are asked to rate
its importance on a 1-10 scale (see Figure 3).
The third module focuses on behavioral change in-
cluding techniques such as setting clearly specified goals,
actions on specific dates, strategies to help with control-
ling and overcoming cravings, refusal skills, managing a
‘slip’, and an action plan to deal with high risk situations.
Safety & security
The intervention is not intended to provide emergency
treatment, and the participant information sheet and
website for the study provide emergency contact num-
bers for appropriate providers. If distressed participants
contact the research team, the Centre for Mental Health
Research has a written protocol to guide members of
staff in handling the situation. All user data collected via
the study website and the online intervention are se-
curely stored according to a written protocol, and access
to data is limited to research staff who are named on the
ethics protocol [44].
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Discussion
To the best of our knowledge, this is the first internet
intervention developed specifically for users of ATS.
Outcomes will be evaluated against critical measures, in-
cluding changes in the use of ATS, improved mental
wellbeing and quality of life. The randomized design and
6 month follow-up will allow firm conclusions to be
drawn and, if successful, will justify the dissemination of
the site into an effectiveness trial, i.e. under ‘real world’
conditions, and with evaluation to 12 months. There is
already evidence that it is feasible and effective to transi-
tion internet interventions for substance abuse from
randomized trials into open access sites to provide
resources to the general community, at least in the case
of cessation of smoking [45].
There are a number of ethical issues that are common
to internet interventions. Firstly, for ethical reasons the
minimum age for participants is 18 years. Although par-
ticipants are explicitly asked to confirm that they are
aged 18 years or older, it will not be possible to ensure
that all participants are adults [46]. Secondly, since parti-
cipants are recruited via an online mechanism, the ex-
tent that consent is ‘informed’ is not as transparent
compared with face-to-face recruitment. However, the
consent process includes multiple tick boxes covering
critical issues and provides direct contact details of the
chief investigator, as recommended [47]. Third, it is not
possible to gauge if participants have become distressed
by the content or activities of the intervention and pro-
vide clinical support. Therefore, the information sheet
and resources in the trial web-site contain contact
details for relevant agencies. Fourth, the study uses a
waitlist control rather than an ‘attention control’, which
means that exposure to the experimental setting could
account for any changes observed, rather than the con-
tent of the modules.
It has been suggested that internet interventions incur
a greater level of attrition than face-to-face interventions
which threatens their internal validity [48]. The study
has been designed to be ‘front-loaded’ with screening
and baseline questionnaires applied before randomization
and entry into the study; this may encourage early drop
out by those with low motivation [48], but may limit sub-
sequent generalization to more motivated participants.
The use of MMRM analysis maximizes the use of available
data collected during the study to minimize biases asso-
ciated with attrition. A particular concern for internet
interventions in the substance use domain is that of self-
Figure 2 Screen shot from module 1 – money problems.
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report of drug use without the potential to use biochem-
ical verification (i.e. urine samples) as often used in face-
to-face intervention trials. Nevertheless, there are data to
support the reliability and validity of self-reported illicit
drug use: indeed self-reports can reveal a greater extent of
drug use than biochemical screening, with most illicit
drugs only detectable for a short period [49].
If the intervention is effective, it will offer advantages over
conventional, face-to-face interventions in that internet
interventions can provide treatment virtually nationwide. In
Australia, 80% of the population already has access to the
internet at home with further access provided by public fa-
cilities such as libraries [50]. There is also the potential for
access to the site by an increasing proportion of the popula-
tion of the world. Further, the anonymous nature of the
intervention may reach participants who are reluctant to
engage with traditional drug treatment services due to fear
of stigmatization or the belief that the services offered are
not appropriate for those with ATS related problems rather
than alcohol or opioid problems.
Status of the trial
Recruitment is planned to commence in mid-2012
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